Taiwanese healthtech startup dBio joins Luxembourg’s business ecosystem with advanced AI-powered wearables for health and sports performance monitoring.
Lena Mårtensson
Taiwanese startup Decentralized Biotechnology Intelligence (dBio), known for its advanced wearable health technologies, has officially joined Luxembourg’s dynamic business ecosystem by establishing its European headquarters and AI research centre in the Grand Duchy. This move marks a key milestone in the company’s international expansion and highlights Luxembourg’s appeal as a hub for cutting-edge innovation. The company received support from Luxinnovation, the House of Entrepreneurship and the Luxembourg Trade and Investment Office in Taipei.
Wearable devices are increasingly popular tools for monitoring health and athletic performance, yet few offer the level of precision and insight that elite users demand. dBio’s solutions, powered by the Artificial Intelligence of Things (AIoT), aim to bridge this gap.
“The best athletes today strive to improve their performance with just that small percentage that makes the difference,” says Hubertus Hoyt, former Vice President and General Manager of Nike Western Europe and EMEA, who recently joined dBio as Board Advisor. “dBio aims to provide the specific information they need.”
The company’s flagship product, gMOT Cloud, is a smart insole featuring AI-enhanced dynamic motion sensors. It delivers real-time data on foot pressure, centre of gravity, exercise intensity, and caloric expenditure. The insole’s ultra-thin, ergonomic design ensures all-day comfort, while its companion mobile app provides users with live updates, performance analytics, and personalised training recommendations.
The best athletes today strive to improve their performance with just that small percentage. dBio aims to provide the specific information they need.
Hubertus Hoyt, dBio
Another standout product is StethoCloud, dBio’s lightweight AI-powered wearable stethoscope. Weighing just 15 grams, the discreet device continuously monitors heart sounds and sends alerts in case of irregularities. It syncs with a mobile app that records and analyses data, notifying pre-set contacts if abnormalities are detected—making it particularly suited to telemedicine and palliative care applications.
dBio takes pride in its in-house development model, with over 75 registered patents protecting its technology. Its multidisciplinary team of around 25 staff includes AI specialists, hardware engineers, and experts in electronics and semiconductors. Currently tailoring products to individual client needs, the company is now preparing for mass production and expansion beyond Asia.
Luxembourg will serve as the European base for these efforts. The new AI research centre will focus on adapting dBio’s technologies for European markets, particularly in sports such as golf and cycling. As part of this initiative, the company has partnered with LUNEX University of Applied Science, which specialises in physiotherapy, sport and exercise science, and sport management. Additional research collaborations in Luxembourg are also being explored.
“The direction where Europe – and especially Luxembourg – is heading aligns perfectly with our vision,” says Edward Chou, Executive Assistant to the Chairman of dBio.
At a press conference announcing dBio’s arrival, Mario Grotz, CEO of Luxinnovation, welcomed the company into the ecosystem. “The Luxembourg ecosystem is a strong match for your work,” he said. “Luxinnovation will continue to guide you, connect you with key players and help you find the right partners — in Luxembourg and beyond.”
Photo credits: dBio
